• Explore /
  • Poster
  • / Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).

Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).

Abstract Poster

Authors

null

Marion Alcantara

Institut Curie, Saint-Cloud, France

Marion Alcantara , Marion Chevrier , Fabrice Jardin , Anna Schmitt , Caroline Houillier , Lucie Oberic , Olivier L. Chinot , Franck Morschhauser , Frederic Peyrade , Roch Houot , Christine Foulon , Estelle Chauvin , Herve Ghesquieres , Carole Soussain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04446962

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7566)

DOI

10.1200/JCO.2023.41.16_suppl.7566

Abstract #

7566

Poster Bd #

117

Abstract Disclosures

Similar Posters

First Author: Jon Glass

First Author: Jane N. Winter

First Author: Shaha Nabeel

First Author: Nicholas James Short